A memorandum of understanding was signed by the Banque Misr Foundation for Community Welfare with the National Institute for Research on Endemic Disease and Liver to support treatment and tests for patients with hepatitis C. In particular, teenagers aged between 12 and 18 years of age will be targeted, after they have received the appropriate treatment for this age group. In April, the International Food and Drug Administration declared that the medication Harvoni should be used to treat hepatitis patients in this age group.